Effect and safety of conversion from Candesartan to Azilsartan in renal transplant recipeints

Effect and safety of conversion from Candesartan to Azilsartan in renal transplant recipeints - Conversion to Azilsartan in kidney trasnplant recipients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008989

Enrollment

Registered

2012-10-09

Start date

2012-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertensive patient

Interventions

20mg Azilsartan qd for 12wks,40mg qd for 40wks 8mg Candesartan qd for 52wks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Renal transplant recipients with grater than 200mg/day of urine protein despite of the treatment of 12mg Candesartan qd

Exclusion criteria

Exclusion criteria: 1)Past medical history of hypersensitivity to azilsartan 2)Pregnant,lactating,and possibly pregnant women and those planning to become pregnant 3)Judged as ineligible by clinical investigators

Design outcomes

Primary

Measure	Time frame
Urine protein before,3 months,6 months,and 12 months after the conversion	—

Secondary

Measure	Time frame
Blood pressure,albumin,creatinen,potasium,hemoglubin,plasma renin activity,plasma aldosterone concentarion and MCP-1 before,3 months,6 months,and 12 months after the conversion	—

Countries

Japan

Contacts

Public ContactYoichi Kakuta

Osaka University Greduate School of Medicine Department of Urology

kakuta@uro.med.osaka-u.ac.jp06-6879-3531

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026